ClinicalTrials.gg
CompletedNCT02999958AntioxidantsUpdated Dec 3, 2018

Adding Antioxidants Into Human Sequential Culture Media System

An interventional study of Antioxidants in Culture Media, Blastocyst and Antioxidants, sponsored by Vitrolife. Completed at 2 sites in Japan. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2018-12-03.

Sponsored by Vitrolife · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Upon collection, human oocytes are fertilized and culture up to the blastocyst stage, followed by transfer and / or cryopreservation. Culture media systems have been developed that support each step of this process. Although these culture media systems try to mimic the natural environment, several components of the in-vivo situation are not present in today´s media. One such component is anti-oxidants that may protect embryos against damage by reactive oxygen species.

This investigation aims to compare blastocyst development using 2 different types of culture media systems, one of which contains antioxidants. Patients having at least eight oocytes and meeting other inclusion criteria can be included in this investigation.

It is a prospective randomized multicenter study randomly dividing oocytes into two groups and assessing parameters of embryo development from fertilization up to blastocyst formation until day six. Embryos with acceptable developmental characteristics can be transferred into the uterus or cryopreserved for later use.

The investigation is designed as a superiority study comparing utilization rate of blastocysts per normally fertilized oocyte using both media systems. In patients receiving embryo transfer in the fresh treatment cycle, detection of clinical pregnancy by ultrasound after 12 weeks gestation is the final endpoint of the investigation.

Read the detailed description

Study objective:

Study comparing blastocyst development on the same cohort of oocytes using two different media systems, sequential G-Series media versus sequential G-Series media supplemented with antioxidants.

Primary endpoint:

Percentage of good quality blastocysts (GQB) per fertilized oocyte on day 5.

Secondary endpoints:

Embryo development day 3, 5 and 6 Embryo quality day 3, 5 and 6 Total blastocyst formation (day 5 and day 6) Utilization rate (embryos available for transfer and cryopreservation) Biochemical pregnancy rate Implantation rate Clinical pregnancy rate

Setup:

Prospective oocyte sibling, superiority study

MATERIALS AND METHODS

Intervention:

New type of embryo culture media used for in vitro culture of human IVF embryos.

Power analysis:

The planning and the power analysis was made together with a statistician, Nils-Gunnar Pehrsson.

From retrospective data using simulation, the intra individual SD for the difference in % GQB between the two media strategies was estimated to 32%. In order to find a difference in 8% in GQB between the two media with power 80% with paired T-test 128 couples will be needed.

Randomization:

Couples will be enrolled in the study at oocyte pick up (day 0). A minimum of 8 cumulus-oocyte-complexes is required for participation.

Stratified randomization of the oocytes by couple will be performed. For each couple the oocytes will be numbered.

These oocytes for each couple will then be block (by two) randomized to the two media types; A (Traditional G-Series media system = Control) and B (G-Series media system with antioxidant = intervention). In both groups traditional culture will be performed. Allocation will be performed in a 1:1 ratio according to a unique randomization list for each couple.

Blinding:

To minimize possible bias for the primary outcome (GQB D5) the embryologist performing the morphological evaluation on day 5/6 will not know which group the embryos belong to.

Both the physician and the couple will be blinded in respect to from which group an embryo was selected for transfer.

IVF treatment procedure:

A traditional IVF treatment will be performed including ovarian stimulation and oocyte pick-up using the standard methods at the clinics.

Embryo assessment on day 3 according to Alpha/ESHRE consensus criteria and on day 5 according to Gardner score.

Morphological scoring Embryo development and morphology on day 3 will be scored based on the Alpha/ESHRE Consensus criteria. Blastocyst development and morphology will be scored according to a published scoring system for blastocysts and will be documented with individual photos of each blastocyst. Embryo \& Blastocyst scoring will be performed under an inverted microscope on day 3 and days 5 \& 6, respectively. Blastocysts that have a score equal or higher than 3BB are considered as GQB.

DOCUMENTATION All patients participating in the study will be documented on a computerized CRF. This document will contain study-specific relevant clinical and laboratory data from the specific IVF cycle.

STATISTICAL ANALYSIS Both an Intention-to-Treat (ITT) population and a Per Protocol (PP) population will be defined. Primary efficacy variable in this superiority study will be difference in % GQB between the two media types for each couple. Primary statistical analysis will be two-sided paired T-test regarding the mean of difference in % GQB between Standard sequential culture media and Antioxidant media on the ITT population. A two sided 95% confidence interval for the mean difference in % GOB between the two media will be calculated. All significance tests will be two-sided and conducted at the 5% significance level.

02

Conditions studied

  • Culture Media
  • Blastocyst
  • Antioxidants
  • Embryo
  • Human
  • Oxygen
03

In context

Lead sponsor

Vitrolife is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum eight cumulus-oocyte-complexes.
  • Couples with female, male or unexplained infertility intending to undergo IVF
  • The couple should have received verbal and written information/consent about the study.
  • Blastocyst culture and embryo transfer is decided.
  • If the couple fulfills the criteria above their consent to participate must be given and documented in the couple's medical journal.

Exclusion criteria

Exclusion Criteria:

  • Previous participation in the study
  • PGD/PGS
  • Surgically retrieved sperm cells (TESA / TESE)
  • If split IVF is needed
  • Less than eight cumulus-oocyte-complexes
  • More than thirty cumulus-oocyte-complexes
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
128 participants (actual)

Study arms

  • No intervention
    Control

    Sequential culture media without addition of antioxidants

  • Active comparator
    Treatment

    Sequential culture media with the addition of antioxidants

    Biological: Antioxidants

Interventions

  • BiologicalAntioxidants

    In the Treatment Arm, the G-Series culture media system will be used with antioxidants

    Also known as: Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC), alpha-Lipoic acid (ALA)

06

What researchers measure

Primary outcomes

  1. Percentage of good quality blastocyst (GQB) per fertilized oocyte on day 5

    Time frame: 7 months

Secondary outcomes

  1. Embryo development on day 3, 5 & 6

    Time frame: 7 months

  2. Embryo quality on day 3, 5 & 6

    Time frame: 7 months

  3. Total blastocyst rate

    Time frame: 7 months

  4. Blastocyst utilization rate per fertilized oocyte

    Time frame: 7 months

  5. Biochemical pregnancy rate

    Time frame: 8 months

  6. Clinical pregnancy rate

    Time frame: 9 months

  7. Implantation rate

    Time frame: 8 months

07

Study locations

2 sites
  • Kuramoto Women´s Clinic
    Fukuoka, 8120013, Japan
  • Kiba Park Clinic
    Tokyo, 135-0042, Japan
08

References and documents

Publications

  • Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000 Jun;73(6):1155-8. doi: 10.1016/s0015-0282(00)00518-5. PubMed 10856474 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in May 2018, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2016
First posted
Dec 21, 2016
StartActual
Dec 2016
Primary completionActual
May 2018
CompletionActual
May 2018
Last update
Dec 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02999958
Lead sponsor
Vitrolife
Responsible party
Sponsor
First posted
Dec 21, 2016
Start date
Dec 2016
Primary completion
May 2018
Completion
May 2018
Last update
Dec 3, 2018

Study contacts

A Yoshida, MD, PhD
principal investigator · Kiba Park Clinic, Tokyo

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Antioxidants

Start the discussion